prikaz prve stranice dokumenta Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation
  Download
PDF 658.47 KB
master's thesis
Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation
2024. urn:nbn:hr:171:067040
Schwerdt, Amelie
University of Split
School of Medicine

Cite this document

Schwerdt, A. (2024). Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:067040

Schwerdt, Amelie. "Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:067040

Schwerdt, Amelie. "Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:067040

Schwerdt, A. (2024). 'Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation', Master's thesis, University of Split, School of Medicine, accessed 12 December 2024, https://urn.nsk.hr/urn:nbn:hr:171:067040

Schwerdt A. Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation [Master's thesis]. Split: University of Split, School of Medicine; 2024 [cited 2024 December 12] Available at: https://urn.nsk.hr/urn:nbn:hr:171:067040

A. Schwerdt, "Value of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation", Master's thesis, University of Split, School of Medicine, Split, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:171:067040

Please login to the repository to save this object to your list.
Metadata
TitleValue of circulating tumor cell DNA in HPV-associated anal carcinoma for monitoring treatment effects and detection of disease relapses after treatment with definitive chemoradiation
Title (english)Značenje DNA cirkulirajućih tumorskih stanica u HPV-asociranom analnom karcinomu za praćenje učinka liječenja i detekciju recidiva bolesti nakon liječenja definitivnom kemoradioterapijom
AuthorAmelie Schwerdt
MentorGeorg Gerhard Grabenbauer (mentor)
Committee memberJohannes Brachmann (predsjednik povjerenstva)
Committee memberDoris Rušić (član povjerenstva)
Committee memberMarino Vilović (član povjerenstva)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2024-07-11, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Radiotherapy and Oncology
Abstract
Objectives: The aim of this study was to characterize the potential of cfDNA via liquid biopsy (LB) in patients with HPV-associated anal carcinomas. Specifically, its use as cancer biomarker for therapy surveillance and as early indicator of recurrence after chemoradiation (CRT) was evaluated. Materials and methods: The major part of this study consisted of a thorough literature analysis based on the research topic. An electronic search of online databases was performed to obtain key literature on the topics HPV-associated cancer and LB. The academic database PubMed and search engines such as Google Scholar deemed most appropriate for the research topic were selected. The systematic literature search was executed in selected databases and search engines using the predefined search strategies. The minor part of this study was conducted in form of a prospective pilot study that aimed to evaluate the feasibility of LB in monitoring HPV-induced anal and to a small amount cervical carcinomas before and after CRT. The study was associated and grounded on data from the Departments of Radiation Oncology and Pathology of the hospital in Coburg, Germany. Results: Many studies investigated HPV16-associated anal carcinoma and used ddPCR technology. Some studies also included other HPV-associated tumors such as cervical, oropharyngeal and vulval. The main focus of published studies is the investigation of the clinical applicability of LB regarding treatment response and disease progression monitoring. Cohort size and the post-therapy observation time were the main limitation factors in the described studies. The experimental pilot study primarily focused on HPV16-associated anal carcinoma treated with CRT. After completion of CRT, all cases (n=12) reached complete clinical and biochemical remission. Short post-therapeutic observation time and small cohort size were the main limitations. Conclusion: The findings of the literature analysis underscore the potential of LB, particularly ddPCR-based HPV16 ctDNA analysis, in enhancing prognostication, treatment monitoring, and early detection of disease recurrence in anal squamous cell carcinoma patients. The pilot study demonstrated that the initial detection of HPV16 ctDNA by LB predisposes successful therapy monitoring and facilitates disease progression observation following CRT. This work introduced LB-based HPV16 detection in patients with anal squamous cell carcinomas for therapy monitoring and outcome prediction in the Department of Radiation Oncology and Pathology in the Hospital of Coburg.
Abstract (croatian)
Ciljevi: Cilj ove studije bio je karakterizirati potencijal cfDNA putem tekuće biopsije (LB) kod pacijenata s HPV-povezanim analnim karcinomima. Konkretno, procijenjena je njegova upotreba kao biomarkera raka za nadzor terapije i kao rani pokazatelj recidiva nakon kemoradioterapije (CRT). Materijali i metode: Glavni dio ove studije sastojao se od temeljite analize literature na temelju istraživačke teme. Elektronska pretraga online baza podataka obavljena je kako bi se dobila ključna literatura o temama raka povezanog s HPV-om i tekuće biopsije (LB). Odabrane su akademska baza podataka PubMed i tražilice kao što je Google Scholar koje su smatrane najprikladnijima za istraživačku temu. Sustavna pretraga literature provedena je u odabranim bazama podataka i tražilicama koristeći unaprijed definirane strategije pretrage. Manji dio ove studije proveden je u obliku prospektivne pilot-studije koja je imala za cilj procijeniti izvedivost LB u praćenju analnih karcinoma uzrokovanih HPV-om i u manjoj mjeri cervikalnih karcinoma prije i nakon kemoradioterapije (CRT). Studija je bila povezana sa podacima iz odjela za radijacijsku onkologiju i patologiju bolnice u Coburgu, Njemačka. Rezultati: Većina studija istraživala je analni karcinom povezan s HPV16 i koristila ddPCR tehnologiju. Tri studije su također uključivale druge tumore povezane s HPV-om, kao što su cervikalni, orofaringealni i vulvalni. Glavni fokus objavljenih studija je istraživanje kliničke primjenjivosti tekuće biopsije (LB) s obzirom na reakciju na liječenje i praćenje razvijanja bolesti. Veličina kohorte i vrijeme postterapijskog praćenja glavni su ograničavajući faktori u opisanim studijama. Pilot-studija je prvenstveno bila usmjerena na analni karcinom povezan s HPV16 koji je liječen kemoradioterapijom (CRT). Nakon završetka CRT-a, svi slučajevi (n=12) postigli su potpunu kliničku i biokemijsku remisiju. Kratko postterapijsko vrijeme praćenja i mala veličina kohorte bili su glavni ograničavajući faktori. Zaključci: Nalazi analize literature naglašavaju transformacijski potencijal tekuće biopsije (LB), osobito analize HPV16 ctDNA temeljene na ddPCR-u, u poboljšanju prognoze, praćenju liječenja i u ranom otkrivanju recidiva bolesti kod pacijenata s analnim pločastim staničnim karcinomom. Pilot-studija je pokazala da početno otkrivanje HPV16 ctDNA putem LB-a predisponira uspješno praćenje terapije i olakšava praćenje razvijanja bolesti nakon CRT-a. Ovaj rad je uveo otkrivanje HPV16 pomoću LB-a kod pacijenata s analnim pločastim staničnim karcinomom za praćenje terapije i predviđanje ishoda na odjelu za radijacijsku onkologiju i patologiju u bolnici Coburg.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:171:067040
Study programmeTitle: Medical Studies in English
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Embargo expiration date: 2024-07-11
Terms of useLicence In copyright icon
Created on2024-07-10 07:15:08